Block & Leviton is investigating Candel Therapeutics for potential securities law violations related to allegedly misleading statements about its Biologics License Application (BLA) for aglatimagene. The investigation stems from a delay in the BLA submission, which was initially expected by November 2026 but is now pushed to mid-2027, leading to a stock price decline.
Block & Leviton has launched an investigation into Candel Therapeutics (CADL) regarding potential securities law violations. The core issue is whether the company provided accurate information to investors about the readiness of its Biologics License Application (BLA) for aglatimagene, specifically concerning manufacturing process validation and submission timelines. This investigation was triggered by the company's announcement on November 12, 2026, that the BLA submission would be delayed from its original target to mid-2027, which subsequently led to a decline in CADL's stock price. For traders, this represents a short-term negative catalyst due to increased legal uncertainty and potential financial liabilities for Candel Therapeutics, as well as a blow to investor confidence regarding the company's development pipeline. The long-term implications depend on the outcome of the investigation and the eventual success of the BLA, but immediate sentiment is likely to remain bearish.